PT-141 (Bremelanotide): Uses, Dosing, Side Effects, and How It Compares to Kisspeptin-10, Oxytocin, and DSIP

What Is PT-141 (Bremelanotide) and How Does It Work?

PT-141, the research name for bremelanotide, acts on melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system to increase sexual motivation. Unlike phosphodiesterase-5 inhibitors, it does not dilate peripheral blood vessels as its primary action; it changes the brain's appetitive drive toward sexual activity. The FDA granted approval in June 2019 under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women.

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It was originally synthesized as a derivative of Melanotan II during skin-tanning peptide research at the University of Arizona. Investigators noticed that study participants reported spontaneous erections and increased sexual desire, which redirected the research program entirely [1].

The melanocortin system sits upstream of both dopaminergic and opioidergic circuits that regulate reward and motivation [2]. Activation of MC4R in the medial preoptic area of the hypothalamus appears to be the dominant mechanism. Animal studies showed that MC4R knockout mice display markedly reduced copulatory behavior, and selective MC4R agonists restored it dose-dependently [3]. That central mechanism explains why bremelanotide can increase desire even in women whose low libido has a predominantly psychological or relational component, not just a physiological one.

A 2019 phase-3 trial published in the Journal of Sexual Medicine (N=1,247) found that women receiving bremelanotide 1.75 mg had a statistically significant improvement in satisfying sexual events per month compared with placebo (P<0.001), alongside reduced distress about low desire measured on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [4].

FDA-Approved Indication: HSDD in Premenopausal Women

The RECONNECT program, comprising two identical phase-3 randomized controlled trials, formed the basis of the FDA submission for Vyleesi. Across both studies (combined N=1,247), bremelanotide 1.75 mg subcutaneous injection produced a mean increase of 0.5 satisfying sexual events per month above placebo (P<0.001) and a 0.3-point greater reduction on the 13-item FSDS-DAO distress subscale (P<0.001) [4]. These numbers are modest in absolute terms but were judged clinically meaningful by the FDA because HSDD significantly impairs quality of life and had no approved pharmacological option for premenopausal women before Vyleesi [5].

The prescribing information specifies acquired, generalized HSDD only. "Acquired" means the desire problem developed after a period of normal sexual desire. "Generalized" means it occurs regardless of partner, type of stimulation, or context. Clinicians should not prescribe bremelanotide for situational or partner-specific loss of desire [5].

Flibanserin (Addyi) is the other FDA-approved HSDD agent; it requires daily oral dosing and carries a boxed warning about alcohol interaction. Bremelanotide is on-demand, which many patients prefer [5].

Dosing Protocol and Administration

The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity [5]. The prefilled autoinjector (Vyleesi) simplifies self-administration. Patients should not use more than one dose per 24-hour period, and the FDA label recommends limiting use if nausea consistently requires antiemetic rescue.

Off-label compounded bremelanotide for men is commonly prepared at 1.0 to 2.0 mg per injection, though these doses are not supported by an approved labeling [6]. Prescribers sourcing compounded peptides should verify the pharmacy holds a 503B outsourcing facility registration with the FDA [7].

Blood pressure follows a predictable pattern after injection: systolic pressure falls by roughly 6 mmHg within the first 12 minutes, then rises 6 mmHg above baseline by 1 hour, returning to baseline by 12 hours [5]. Patients with cardiovascular disease or uncontrolled hypertension should not use bremelanotide.

Side Effects and Safety Profile

Nausea is the most reported adverse event. In RECONNECT, 40% of bremelanotide users reported nausea versus 1% of placebo users; 13% rated it severe [4]. Flushing occurred in 20% and headache in 11% [4]. Focal hyperpigmentation of the face, gums, or breasts appeared in 1% of participants after multiple doses; the FDA label warns about this effect explicitly [5].

Transient increases in blood pressure following the blood-pressure dip are the main cardiovascular concern. The FDA placed a specific warning in the label about patients with high cardiovascular risk [5]. The drug is also contraindicated in pregnancy because of potential fetal harm observed in animal reproductive toxicity studies at exposures approximately 16 times the human clinical dose [5].

Off-Label Use in Men

No randomized controlled trial of sufficient size has been completed in men with erectile dysfunction or low libido as of the 2025 review date. A phase-2 dose-escalation study by Diamond et al. (N=90) found that subcutaneous bremelanotide 0.025 mg/kg produced erections in 80% of men with psychogenic erectile dysfunction compared with 5% on placebo, with a mean erectile function domain score increase of 6.2 points on the IIEF [6]. Larger confirmatory trials were not pursued by Palatin Technologies, but prescribers continue to use this data as an off-label rationale.

Men with low desire secondary to hypogonadism should have testosterone deficiency corrected first, as bremelanotide does not address androgen deficiency directly [8].

Kisspeptin-10: The Hypothalamic Signal Upstream of Bremelanotide

Kisspeptin-10 is the shortest bioactive fragment of the kisspeptin family (encoded by the KISS1 gene) and acts on the G-protein-coupled receptor GPR54 (KISS1R) in GnRH neurons of the hypothalamus [9]. Where bremelanotide acts at the melanocortin node of sexual motivation, kisspeptin-10 targets reproductive axis priming by driving pulsatile GnRH and downstream LH/FSH secretion.

A key study by Dhillo et al. published in The Journal of Clinical Endocrinology and Metabolism (N=14 healthy men) found that a single intravenous infusion of kisspeptin-10 at 1 nmol/kg/h produced a 4-fold increase in mean LH pulse amplitude (P<0.001) and a significant rise in plasma testosterone at 90 minutes [10]. This reproductive-axis stimulation distinguishes kisspeptin-10 from bremelanotide, which does not meaningfully alter LH or testosterone.

Beyond hormone secretion, kisspeptin-10 may modulate sexual aversion and emotional processing. A 2017 neuroimaging study by Comninos et al. (N=29 healthy men, randomized crossover) found that intravenous kisspeptin-10 infusion increased hypothalamic and limbic activation in response to sexual stimuli on fMRI, and simultaneously reduced amygdala activation to aversive stimuli compared with saline (P<0.05) [11]. That dual effect, enhancing sexual approach while dampening disgust or fear responses, makes kisspeptin-10 conceptually distinct from both bremelanotide and phosphodiesterase-5 inhibitors.

Clinical availability of kisspeptin-10 is limited to investigational settings in the United States as of 2025. No FDA-approved formulation exists. Research groups have used intravenous infusion protocols, and some compounding pharmacies prepare subcutaneous formulations for off-label use under physician supervision, though the evidence base for subcutaneous dosing is thin.

Therapeutic Oxytocin: Bonding, Orgasm, and Stress

Oxytocin is a nine-amino-acid neuropeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released from the posterior pituitary [12]. Its established clinical uses include labor induction (intravenous Pitocin) and postpartum hemorrhage prevention, both FDA-approved. The growing off-label therapeutic interest centers on intranasal delivery, which allows oxytocin to cross the blood-brain barrier through olfactory and trigeminal nerve pathways and reach limbic structures including the amygdala and nucleus accumbens [13].

A meta-analysis by Quintana et al. published in Neuroscience and Biobehavioral Reviews (k=23 RCTs, N=1,529) found that intranasal oxytocin significantly reduced self-reported anxiety compared with placebo (standardized mean difference = 0.34 to 95% CI 0.16 to 0.52, P<0.001) [14]. Effects on social cognition were more heterogeneous across studies.

Sexual applications of oxytocin are biologically plausible. Oxytocin is released at orgasm in both sexes, and plasma levels correlate with subjective orgasm intensity in women [15]. Intranasal oxytocin 24 IU administered before partnered intimacy has been studied in small trials for orgasmic dysfunction, with mixed but generally positive directional results [15]. Doses used in research range from 24 IU to 40 IU intranasally; clinical prescribers often use 20 to 40 IU applied 20 to 30 minutes before the intended activity.

Unlike bremelanotide, oxytocin does not have a significant blood-pressure warning, but it can cause mild hyponatremia with repeated high-dose use because of its structural similarity to vasopressin and weak V2 receptor activity [12]. Patients with cardiac or renal conditions warrant monitoring.

Comparing bremelanotide and therapeutic oxytocin directly: bremelanotide targets desire (the appetitive phase), while oxytocin most likely strengthens bonding, orgasm intensity, and emotional closeness during and after activity. They address different phases of the sexual response cycle and could theoretically complement each other, though no head-to-head clinical trial has been published.

DSIP (Delta Sleep-Inducing Peptide): Sleep Architecture and Stress-Axis Modulation

DSIP is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood by Monnier et al. in 1977 [16]. Its name reflects its original characterization as a promoter of slow-wave (delta) sleep when infused into animals. Human evidence is more limited, but the peptide has attracted clinical interest for sleep disorders, stress-axis dysregulation, and pain modulation.

A crossover study by Schneider-Helmert and Spinweber (N=18 insomnia patients) found that intravenous DSIP 25 nmol/kg administered over 20 minutes reduced sleep latency and increased delta sleep time compared with saline on polysomnography (P<0.05) [17]. The effect appeared to persist over several nights post-infusion, suggesting a modulating rather than sedating mechanism, which distinguishes DSIP from benzodiazepines or z-drugs that act via GABA-A receptor potentiation [17].

DSIP also appears to modulate the hypothalamic-pituitary-adrenal (HPA) axis. Concentrations of DSIP in human plasma follow a circadian rhythm inversely correlated with cortisol, with nadirs during peak cortisol secretion in the morning [18]. Animal models show that exogenous DSIP attenuates stress-induced corticosterone rises and reduces withdrawal symptoms in opioid-dependent rats, pointing toward a stress-buffering role [18].

No FDA-approved DSIP product exists. Compounded subcutaneous formulations circulate in the peptide therapy community, typically dosed at 100 to 500 mcg before sleep. The absence of large-scale human RCTs means prescribers treating DSIP as a therapeutic agent are working well beyond published evidence, and patients should be counseled accordingly.

In the context of this article's broader subject, DSIP's relevance to sexual health is indirect: chronic sleep deprivation and HPA-axis overactivation are independent risk factors for low testosterone, reduced libido, and impaired orgasmic function [19]. Correcting disordered sleep through any means, including DSIP if its benefits in larger trials are confirmed, may improve the conditions that bremelanotide or kisspeptin-10 are then asked to address.

Comparing PT-141, Kisspeptin-10, Oxytocin, and DSIP Side by Side

These four peptides occupy distinct positions in sexual and reproductive health:

PT-141 (bremelanotide): Central melanocortin agonist. Directly increases sexual desire and motivation. FDA-approved for HSDD in premenopausal women. On-demand subcutaneous injection, 1.75 mg, 45 minutes before activity. Best evidence for desire-phase dysfunction.

Kisspeptin-10: Hypothalamic GnRH secretagogue. Increases LH, FSH, and testosterone pulsatility. Reduces sexual aversion via limbic modulation. No approved formulation; investigational IV or off-label subcutaneous. Best fit for reproductive-axis priming and approach-avoidance aspects of sexual dysfunction.

Oxytocin: Posterior pituitary neuropeptide. Strengthens trust, bonding, and orgasmic intensity. FDA-approved only for obstetric indications. Intranasal 20 to 40 IU off-label for intimacy and anxiety reduction. Best fit for consummatory-phase and relational aspects of sexual dysfunction.

DSIP: Sleep-modulating nonapeptide. Increases delta-wave sleep, attenuates HPA-axis reactivity. No approved formulation. Best fit as an adjunct addressing sleep and stress drivers of low libido rather than desire or arousal directly.

A patient with HSDD who also reports chronic insomnia and high relational anxiety might plausibly benefit from DSIP and oxytocin alongside bremelanotide, but no clinical trial has tested this combination and the risk-benefit profile of multi-peptide stacking is unknown.

Patient Selection and Prescriber Considerations

Bremelanotide is appropriate for a premenopausal woman with HSDD who has no cardiovascular contraindications, no history of focal hyperpigmentation disorders, and who prefers on-demand rather than daily dosing [5]. Providers should rule out thyroid disease, depression, relationship distress, and medication side effects (particularly SSRI-induced sexual dysfunction) as primary drivers before prescribing any desire-focused peptide [20].

For men presenting with low libido, a full hormonal workup including total testosterone, free testosterone, LH, FSH, prolactin, and thyroid-stimulating hormone should precede any peptide prescription [8]. If testosterone is below 300 ng/dL by AUA/Endocrine Society thresholds, testosterone replacement should be considered first [8].

Compounded peptides (kisspeptin-10, DSIP, or compounded bremelanotide) sit outside FDA approval, which means the prescriber carries the weight of the off-label decision, and patients must give informed consent that includes acknowledgment of the limited regulatory oversight of compounded products [7].

Monitoring After Starting PT-141

Baseline blood pressure measurement before the first dose is standard practice given the transient BP excursion described above [5]. Patients should be instructed to remain in a comfortable seated or supine position for at least 30 minutes after the first injection to monitor for symptomatic hypotension.

Skin should be inspected at follow-up visits for focal hyperpigmentation, particularly of the face, breasts, and gingiva. If hyperpigmentation appears, discontinuation is recommended because the discoloration can persist for weeks after stopping [5]. Liver function tests are not routinely required, but renal impairment does not appear to alter bremelanotide pharmacokinetics significantly in moderate renal disease based on population PK data from the RECONNECT program [4].

Women of childbearing potential should use contraception during bremelanotide therapy and stop the drug at least one menstrual cycle before attempting conception given the animal reproductive toxicity data [5].